Precision medicine

Caris Life Sciences and ConcertAI Form Broad Partnership Creating Industry-Leading Molecular Oncology Research Platform to Accelerate Drug Development and Novel Research

Retrieved on: 
Monday, January 9, 2023
Deletion, EMR, Partnership, Precision medicine, WES, HRD, MS, Research, Artificial intelligence, Organization, Sequence, MBA, Patient, MSI, AI, TMB, GLOH, Collection, Hematology, Doctor of Philosophy, Medical imaging

IRVING, Texas and CAMBRIDGE, Mass., Jan. 9, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, the leading oncology real-world evidence data and AI technology company, announced a unique partnership to align the two companies' oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.

Key Points: 
  • The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.
  • As the pioneer in precision medicine and molecular profiling, Caris has created a molecular-rich, real-world database of hundreds of thousands of cases that include genomic, transcriptomic and proteomic data.
  • The company's Patient360™ specification has emerged as the reference standard for leading biopharma and other research groups.
  • In addition, the company's AI SaaS solutions for clinical trial design and clinical development studies have emerged as the leading solution for next generation precision oncology trials.

Novo Holdings invests in proteomics technology company, Evosep

Retrieved on: 
Monday, January 9, 2023
Investment fund, Novo Holdings A/S, Partnership, Health, Precision medicine, Drug discovery, Export, Biomarker, Investment, LC-MS, Growth, Patient, Quality of life, Genetics, Diagnosis, Proteomics, Fine chemical, Medical imaging, Renewable energy

COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.
  • The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep's standardised liquid chromatography platform.
  • "We are delighted to have Novo Holdings A/S as a new shareholder in Evosep.
  • We are confident that Evosep, with their advanced technology, will create significant positive change in the healthcare sector."

Novo Holdings invests in proteomics technology company, Evosep

Retrieved on: 
Monday, January 9, 2023
Investment fund, Novo Holdings A/S, Partnership, Health, Precision medicine, Drug discovery, Export, Biomarker, Investment, LC-MS, Growth, Patient, Quality of life, Genetics, Diagnosis, Proteomics, Fine chemical, Medical imaging, Renewable energy

COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 9, 2023 /PRNewswire/ -- Novo Holdings, a leading international life science investor, today announced a $40m investment in Evosep, the bioscience company leading the standardisation of proteomics for clinical use.
  • The proceeds from the investment by Novo Holdings will be used to advance clinical applications of proteomics enabled by Evosep's standardised liquid chromatography platform.
  • "We are delighted to have Novo Holdings A/S as a new shareholder in Evosep.
  • We are confident that Evosep, with their advanced technology, will create significant positive change in the healthcare sector."

OpGen Announces Pricing of $7.5 Million Public Offering

Retrieved on: 
Saturday, January 7, 2023
Precision medicine, Park Avenue, Infection, Security (finance), Form, Series, Form S-1, Prospectus, FDA, 3rd Floor, Nadine Opgen-Rhein, Sale, SEC filing

The closing of the offering is expected to occur on or about January 11, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the offering is expected to occur on or about January 11, 2023, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be approximately $7.5 million.
  • The offering is being made only by means of a prospectus which forms a part of the effective registration statement.

HTG Announces Certain Preliminary 2022 Unaudited Financial Results

Retrieved on: 
Friday, January 6, 2023
HTP, Precision medicine, HTG, Therapy, Pharmaceutical industry

TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.

Key Points: 
  • Cash and cash equivalents of $12.2 million as of December 31, 2022
    TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022.
  • Actual results may differ materially from these preliminary unaudited results as a result of the completion of year-end closing procedures, final adjustments and other developments arising between now and the time that the company’s financial results are finalized, and such changes could be material.
  • In addition, these preliminary unaudited results are not a comprehensive statement of the company’s financial results for the year ended December 31, 2022, should not be viewed as a substitute for full, audited financial statements prepared in accordance with generally accepted accounting principles, and are not necessarily indicative of the company’s results for any future period.
  • The company expects to announce full 2022 financial results in advance of its quarterly conference call in March 2023.

Frontier Medicines Announces Advancement of Second and Third Programs Under Global Partnership with AbbVie

Retrieved on: 
Thursday, January 5, 2023
Secondary research, AbbVie, Patient, Biology, Partnership, Frontier, Proteome, E3, Precision medicine, SAN, Therapy, Pharmaceutical industry

These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform.

Key Points: 
  • These programs harness novel E3 Ligases for targeted protein degradation, through the discovery of small molecules from The Frontier™ Platform.
  • "Our collaboration with Frontier is continuing to make progress against difficult-to-drug protein targets," said Jonathon Sedgwick, Ph.D., vice president and global head, Discovery Research, AbbVie.
  • Started in 2020, the objective of the global partnership is to discover, develop, and commercialize a pipeline of innovative small molecule therapeutics against certain high-interest, difficult-to-drug protein targets.
  • "Our delivery of three programs into lead generation further validates The Frontier™ Platform's ability to systematically discover and deliver small molecules to drug undruggable targets.

Frontier Medicines Advances First Development Candidate, FMC-376, a Uniquely Differentiated Inhibitor of Both Active and Inactive KRASG12C, into IND-Enabling Studies

Retrieved on: 
Thursday, January 5, 2023
Precision medicine, Stritch School of Medicine, Druggability, NCI, Trastuzumab, Rituximab, SAN, Loyola University, Patient, Frontier, AI, Safety, GTP, Internal medicine, IND, Erlotinib, National Cancer Institute, Proteome, Cedars-Sinai Medical Center, Pharmaceutical industry, Genentech, Development

SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company advancing transformative drugs against historically undruggable disease-causing targets, announced the selection of its first development candidate, FMC-376, an oral, covalent small-molecule inhibitor that selectively targets both active (GTP-bound) and inactive (GDP-bound) conformations of KRASG12C. In preclinical studies, FMC-376 retains potency in the context of receptor tyrosine kinase activation, which is likely a major mechanism of non-response and resistance to prior generation inhibitors that only target inactive (GDP-bound) KRASG12C. Preclinical data for FMC-376 supports a potential best-in-class profile for safety and efficacy, with the promise of first-line treatment in both monotherapy and combination use. IND filing for FMC-376 is planned for this year.

Key Points: 
  • Preclinical data for FMC-376 supports a potential best-in-class profile for safety and efficacy, with the promise of first-line treatment in both monotherapy and combination use.
  • Dr. Klein has more than 20 years of oncology drug development experience across industry and academia.
  • At Genentech, Dr. Klein led development and medical affairs for a portfolio of oncology programs including trastuzumab (Herceptin), rituximab (Rituxan), pertuzumab (Perjeta) and erlotinib (Tarceva).
  • She trained in internal medicine at Cedars-Sinai Medical Center and Oncology at the NCI, serving as chief oncology fellow during that time.

Insilico Medicine launches 6th generation Intelligent Robotics Lab to further accelerate its AI-driven drug discovery

Retrieved on: 
Thursday, January 5, 2023
Clinical trial, Fibrosis, Precision medicine, Marquette University Humanoid Engineering & Intelligent Robotics Lab, Automation, Drug development, Research, Quality control, COVID-19, Brain, Biomarker, Robotics, Laboratory, Inflammation, Lifestar, Drug design, PCC, Biology, Industrial park, AI, Insilico Medicine, Machine learning, Therapy, Human, Bias, Pharma, Doctor of Philosophy, Medical device, In silico

New York, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

Key Points: 
  • New York, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine (“Insilico”), a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.
  • The lab will allow Insilico to further accelerate its end-to-end drug discovery and optimize the success rate of its drug development as it moves its novel therapeutics through clinical trials.
  • Insilico Medicine’s lab takes this process one step further to incorporate AI in decision-making and deeply integrate AI with automation, robotics, and biological capabilities to enable a new generation of intelligent robotic labs.
  • Now, Insilico Medicine proposes a comprehensive solution through the Intelligent Robotics Lab.

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

Retrieved on: 
Thursday, January 5, 2023
American College, Precision medicine, Medical genetics, ACMG, American College of Medical Genetics and Genomics, SALT, PPV, Myriad Genetics, DiGeorge syndrome, SCAS, Genetic testing, Prequel, MYGN, Chromosome, Patient, Guideline, Physician, Genetics, NIPS, Fetus, Association for Molecular Pathology v. Myriad Genetics, Inc., Genetic distance, Trisomy, Medical imaging, Genomics

Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.

Key Points: 
  • Myriad Genetics’ Prequel NIPS already offers this screening for SCAs and common microdeletions, such as 22q, for physicians and patients who opt-in, providing a flexible option that is consistent with ACMG's recommendations.
  • FirstGene is a 4-in-1 offering that includes NIPS for chromosomal abnormalities, carrier screening for recessive conditions, simultaneous single-gene assessment of whether the fetus is affected with a condition identified via carrier screening, and feto-maternal blood compatibility.
  • “We’re excited to introduce our FirstGene product in Q3 2023,” said Melissa Gonzales, President, Women’s Health, Myriad Genetics.
  • We are very encouraged to see that initial data supports our view that Prequel provides exemplary PPV for 22q screening via NIPS.”

OpGen Announced 1-for-20 Reverse Stock Split

Retrieved on: 
Wednesday, January 4, 2023
Transfer, Reverse stock split, Precision medicine, EST, Bangladesh Securities and Exchange Commission, Infection, PST, Form, Nadine Opgen-Rhein, Letter, Exercise, Trust, CUSIP, Security (finance)

ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that the Company’s board of directors has approved a 1-for-20 reverse stock split of its shares of common stock (the “Reverse Stock Split”).

Key Points: 
  • ROCKVILLE, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that the Company’s board of directors has approved a 1-for-20 reverse stock split of its shares of common stock (the “Reverse Stock Split”).
  • The Reverse Stock Split will become effective at 12:01 a.m. EST, on January 5, 2023 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis under the Company’s existing trading symbol “OPGN.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 68373L406.
  • The Reverse Stock Split impacts all holders of OpGen’s common stock proportionally and will not impact any stockholders’ percentage ownership of common stock (except to the extent the Reverse Stock Split results in any stockholder owning only a fractional share).
  • Pacific Stock Transfer Company (‘PST’) is acting as paying agent for OpGen with regard to the Reverse Stock Split.